Retrophin revives inhaled oxytocin for schizophrenia, autism
This article was originally published in Scrip
Executive Summary
The early-stage pharmaceutical firm Retrophin, which became a public company only last year, went on a buying spree that was met with skepticism in the stock market to acquire multiple inhaled oxytocin products that will be developed for schizophrenia and autism.